Clinipace CEO, founder steps aside, hands reins over to new blood

Financial consulting firm founder Jason Monteleone will become its new leader.

A full 14 years after founding CRO Clinipace, its longstanding CEO and president, Jeff Williams, is planning to step down.

The chief’s role will be handed over to Jason Monteleone, who founded Pivotal Financial Consulting, a consulting firm with a focus on CROs, while Williams moves into an “expanded advisory role” within the board, according to a statement.

“I am extremely proud of what we have built at Clinipace, but the time has come for me to replace myself and it is my pleasure to welcome Jason Monteleone as CEO,” said Williams.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

“After seeing him in action as a consultant to Clinipace over the last several months, I am confident he will build successfully on our company’s 14-year history and lead us into its next phase of growth.”

Williams has over the past three years been an acquisitive chief, buying up European CRO Accovion as well as Hong Kong CRO Choice Pharma, Paragon Biomedical, PFC Pharma, Regulus Pharmaceutical and Worldwide Clinical Research.

RELATED: Clinipace bags CRO Accovion in its latest global buyout

It now has more than 800 staffers and has completed more than 1,500 clinical trials.

Monteleone added: “I am honored to join Clinipace on the heels of the remarkable accomplishments that Jeff and his organization have achieved. I am confident that the strong foundation he built, and the talented team here, will serve us well as we continue our quest to make Clinipace the leading mid-market CRO.”

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.